Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | UQCRB | P14927 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149558 | 0.95 | DYRK1A (0.45) | DYRK1ABRD4CA1CA2POLB | |
| SCHEMBL3944329 | 0.92 | BRD4 (0.45) | BRD4CA1CA2SERPINE1POLB | |
| SCHEMBL3946013 | 0.92 | BRD4 (0.50) | BRD4CA1CA2SERPINE1POLB | |
| SCHEMBL3945495 | 0.90 | HSD17B10 (0.47) | BRD4CA1CA2SERPINE1POLB | |
| SCHEMBL3951262 | 0.88 | BRD4 (0.43) | DYRK1ABRD4SERPINE1POLBMEN1 | |
| SCHEMBL3950530 | 0.87 | DYRK1A (0.46) | DYRK1ABRD4SERPINE1POLBMEN1 | |
| SCHEMBL3946815 | 0.87 | BRD4 (0.45) | BRD4SERPINE1POLBMEN1KMT2A | |
| SCHEMBL5151354 | 0.87 | CA1 (0.45) | BRD4CA1CA2SERPINE1POLB | |
| SCHEMBL4588427 | 0.86 | BRD4 (0.42) | DYRK1ABRD4SERPINE1POLBMEN1 | |
| SCHEMBL4588422 | 0.86 | BRD4 (0.42) | DYRK1ABRD4SERPINE1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802572-B1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-22 | — | — | EP | claimed |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-06 | — | — | US | claimed |
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | NGUYEN DUY | 2008-01-03 | — | — | US | disclosed |
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | NGUYEN DUY | 2008-01-03 | — | — | US | disclosed |
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | NGUYEN DUY | 2008-01-03 | — | — | US | disclosed |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | ADCY1, ADCY2, ADCY5 | DYRK1A 3897/4885BRD4 3928/4885CA1 1194/4885 |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | ADCY1, ADCY2, ADCY5 | DYRK1A 3897/4885BRD4 3928/4885CA1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.